NCT01058057

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention (PCI) Study 2

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study 2

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: University Hospital, Motol · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) on chronic statin therapy. Patients are randomized into two groups: atorvastatin pre-treatment group (80mg atorvastatin seven days before PCI) and control group (PCI without atorvastatin pretreatment, chronic statin treatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

Detailed description

This randomized study investigates potential protective effect of high dose atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) and chronic statin therapy. Two arms: 1. atorvastatin pre-treatment group (80mg atorvastatin for seven days) 2. control group (without atorvastatin pre-treatment, chronic statin treatment) Primary endpoint: Periprocedural myocardial infarction measured by troponin I level (time frame 24 hours) Secondary endpoint: Periprocedural myocardial infarction measured by creatine kinase myocardial band (time frame 24 hours)

Conditions

• Coronary Artery Disease
• Coronary Angioplasty

Interventions

Type	Name	Description
DRUG	atorvastatin	atorvastatin 80mg p.o. daily seven days before PCI

Timeline

• Start date: 2008-02-01
• Primary completion: 2010-06-01
• First posted: 2010-01-28
• Last updated: 2010-02-03

Locations

1 site across 1 country: Czechia